Liraglutide addition for Chinese patients with type 2 diabetes and minor AIS or high-risk TIA reduced 90-day stroke recurrence and improved functional outcomes.

Question Do glucagon-like peptide–1 receptor agonists (liraglutide) reduce stroke recurrence in patients with type 2 diabetes who have minor acute ischemic stroke or high-risk transient ischemic attack?

Findings In this randomized clinical trial of 636 participants with type 2 diabetes, 25 patients (7.9%) who were randomly assigned to receive standard therapy plus liraglutide and 44 (13.8%) of those who received standard therapy had recurrent stroke at 90 days.

Meaning The results of this randomized clinical trial suggest that, compared with standard therapy, liraglutide might reduce recurrent stroke in patients with type 2 diabetes who had minor acute ischemic stroke or high-risk transient ischemic attack.